The results of that study were published in 1987 in The Journal of Clinical Investigation, listing three scientists: Mojsov first, Weir second, and Habener last
Hsiangkuo Yuan, MD, PhD, study co-author and clinical research director at Jefferson Headache Center
Because retatrutide is not an approved public-use medication and has no FDA-approved consumer vial, concentration, or reconstitution instructions, readers should not apply gray-market vial math or assume online products match the investigational drug used in trials [2], [3]
These interactions highlight the need for customized approaches when starting GLP-1 therapy, ensuring that your treatment plan aligns with your specific health needs
This often means documenting three to six months of participation in a formal weight-management program such as medically supervised programs, working regularly with a dietitian or nutritionist, or following a defined exercise